Stock MRVI MARAVAI LIFESCIENCES HOLDINGS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Maravai LifeSciences Holdings, Inc.

Equities

MRVI

US56600D1072

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-10 pm EDT 		5-day change 1st Jan Change
10.46 USD +6.09% Intraday chart for Maravai LifeSciences Holdings, Inc. +16.61% +59.69%
May. 09 UBS Raises Price Target on Maravai LifeSciences to $8.50 From $6.50, Maintains Neutral Rating MT
May. 09 Baird Adjusts Price Target on Maravai LifeSciences to $10 From $8, Keeps Outperform Rating MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Maravai LifeSciences Announces May and June 2024 Investor Conference Schedule
GL
UBS Raises Price Target on Maravai LifeSciences to $8.50 From $6.50, Maintains Neutral Rating
MT
Baird Adjusts Price Target on Maravai LifeSciences to $10 From $8, Keeps Outperform Rating
MT
Maravai LifeSciences : Conflict Minerals Statement
PU
Maravai LifeSciences : Q1 2024 Earnings
PU
Earnings Flash (MRVI) MARAVAI LIFESCIENCES HOLDINGS LLC Reports Q1 Revenue $64.2M, vs. Street Est of $60.5M
MT
Transcript : Maravai LifeSciences Holdings, Inc., Q1 2024 Earnings Call, May 08, 2024
Maravai LifeSciences Reports First Quarter 2024 Financial Results
GL
Maravai LifeSciences Holdings, Inc. Reaffirms Financial Guidance for the Full Year 2024
CI
Maravai LifeSciences Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
TriLink BioTechnologies and Lonza Enter into Non-exclusive License and Supply Agreement for CleanCap mRNA Capping Technology
AQ
TriLink BioTechnologies® and Lonza Enter into Non-exclusive License and Supply Agreement for CleanCap® mRNA Capping Technology
BU
TriLink BioTechnologies Announces New San Diego Facility for Late Phase mRNA Drug Substance Production
AQ
Maravai LifeSciences Unit Opens New Manufacturing Facility in San Diego
MT
TriLink BioTechnologies® Announces New San Diego Facility for Late Phase mRNA Drug Substance Production
BU
Maravai LifeSciences To Host Earnings Conference Call on Wednesday, May 8, 2024
GL
Craig-Hallum Initiates Coverage on Maravai LifeSciences With Buy Rating, $15 Price Target
MT
RBC Raises Price Target on Maravai LifeSciences Holdings to $15 From $14, Keeps Outperform Rating
MT
Dyadic International Inc. (NASDAQ: DYAI) Funding to Propel Near-Term Revenue Growth Initiatives Highlights in Zacks Small-Cap Research Report
AQ
Transcript : Maravai LifeSciences Holdings, Inc. Presents at KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum, Mar-19-2024 02:15 PM
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MRVI Stock
  4. News Maravai LifeSciences Holdings, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW